6:09 PM
 | 
Sep 26, 2012
 |  BC Extra  |  Company News

GSK, Theravance pulmonary product accepted for review in U.S., EU

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and Theravance Inc. (NASDAQ:THRX) said FDA and EMA accepted regulatory submissions for pulmonary product fluticasone furoate/vilanterol. In the U.S., the partners are...

Read the full 117 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >